{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/feed.json", "description": "Latest Healthcare company headlines from Mexico, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:6ed741a8ec7b1ce2ff45ab0639ea04c82f85c47aa7dab80e782d6748cfcd5f92", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-bmy-wins-191013366.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-bmy-wins-191013366.html", "title": "Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing the first approved CELMoD therapy in this disease setting. See our latest analysis for Bristol-Myers Squibb. The ZENBEXUS approval lands at a time when Bristol-Myers Squibb's momentum has picked up, with the share price at US$64.65 and a 30 day share price return of 13.52%. That builds on a 20.93% year t", "date_published": "2026-08-14T19:10:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:a7e32986cac0d16c450dab2589dc0ebcf0cfb84777fbf47d7139a5263228d988", "url": "https://finance.yahoo.com/m/5d38b910-72a9-371f-9838-f00d13764cf5/pfizer-ceo-caps-post-earnings.html", "external_url": "https://finance.yahoo.com/m/5d38b910-72a9-371f-9838-f00d13764cf5/pfizer-ceo-caps-post-earnings.html", "title": "Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase", "content_text": "Three Pfizer insiders executed transactions directly on the heels of the drugmaker\u2019s second-quarter earnings report. Continue Reading", "date_published": "2026-08-14T17:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a25809d4-86bc-4675-a6db-84b1695cc584/"}]}}, {"id": "source:6e620207c3a2afad9dd3180924e7639b767297f14a66997dfdb37208054e6b2a", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNU2l4cVg2NHhmaUdIZ28wQ2NhTUU4NHFkeW90aHpaTVVXTUJwaWN0RlFNU2N3RWxuZ0VCTVY2eWRQaldJWS04eWM1NWdoZzVlVjJmMVhRMzE0NHc5eW5rcnFadDNUVWd2Y2E1OGxBN291N1lvU0F1eWpHb203WFdkZTBzUEpueTB2YTFpUzhjQ3hRS2ZxTC1CVG9TcG13OU9BeGZ4eGhtdVo0dXhYUnJmWV9IazlFRndJSGpyTU94dDAtTjRpWm1BN3VKLWlMUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNU2l4cVg2NHhmaUdIZ28wQ2NhTUU4NHFkeW90aHpaTVVXTUJwaWN0RlFNU2N3RWxuZ0VCTVY2eWRQaldJWS04eWM1NWdoZzVlVjJmMVhRMzE0NHc5eW5rcnFadDNUVWd2Y2E1OGxBN291N1lvU0F1eWpHb203WFdkZTBzUEpueTB2YTFpUzhjQ3hRS2ZxTC1CVG9TcG13OU9BeGZ4eGhtdVo0dXhYUnJmWV9IazlFRndJSGpyTU94dDAtTjRpWm1BN3VKLWlMUQ?oc=5", "title": "Las acciones de Oscar Health alcanzan un m\u00e1ximo de 52 semanas en 33,12 d\u00f3lares", "content_text": "Las acciones de Oscar Health alcanzan un m\u00e1ximo de 52 semanas en 33,12 d\u00f3lares", "date_published": "2026-08-14T16:22:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "OSCR"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OSCR", "name": "Oscar Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eee6749f-e405-4463-830b-1d0fef8554bf/"}]}}, {"id": "source:7a92c6b19227f993f9d52ad3ce521cc34e10bddf97df9b2d301ee4f7b1588245", "url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "external_url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "title": "SOLV Plans Health Information Systems Business Spinoff to Drive Growth", "content_text": "Solventum SOLV plans to separate its Health Information Systems (HIS) business as part of its portfolio optimization strategy. The move is expected to sharpen the company's focus on its core MedSurg and Dental Solutions businesses while allowing HIS to pursue its growth opportunities as a standalone entity. From an investor perspective, the planned separation could unlock shareholder value by creating a more focused MedTech business and enabling targeted capital allocation toward Solventum's higher-priority growth areas. HIS, which generates $1.4 billion in annual sales and serves more than 75", "date_published": "2026-08-14T15:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SOLV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "SOLVENTUM CORP", "sentiment_url": "https://sharemaestro.com/sentiment/9d43f9f9-d4d6-4fd6-8aa2-6958bab1561b/"}]}}, {"id": "source:2bbfb8e944a917d519505f6e563f6028bb7ec27ee39686f959bc726292ae6904", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-hims-raised-guidance-151415471.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-hims-raised-guidance-151415471.html", "title": "Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset?", "content_text": "Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 6% in extended trading on August 10 after the telehealth company delivered another quarter of rapid growth alongside sharply weaker profitability. Revenue rose 38% year over year to $753.2 million, subscribers increased 19% to 2.89 million, and Monthly Revenue per Average Subscriber climbed 21% to $92. The company also raised its full-year revenue outlook to $3.1 billion to $3.3 billion from $2.8 billion to $3.0 billion. The earnings line told a different story. Hims reported an $86.3 million net loss, equal to 37 cents per share, compared ", "date_published": "2026-08-14T15:14:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:8dc71079705610a28482643141072be9f4ca1d8b708f06563b733048af9fa884", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "title": "Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?", "content_text": "Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. BioMarin Pharmaceutical is one of 914 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to ", "date_published": "2026-08-14T13:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:386cb3630dec68a589d37ae6b2913b5157d6a00dddba542a858ad358a856d9fb", "url": "https://finance.yahoo.com/healthcare/articles/why-did-oscar-health-oscr-133340254.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-did-oscar-health-oscr-133340254.html", "title": "Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?", "content_text": "Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net income of $361.8 million from a $228.4 million loss. The stock recovered 5.1% the following day but still ended 7.3% below its pre-earnings close. The reversal was especially striking because OSCR had climbed roughly 110% in 2026 before the report. Investors had already rewarded the company for appearing to emerge from the Af", "date_published": "2026-08-14T13:33:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "OSCR"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OSCR", "name": "Oscar Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eee6749f-e405-4463-830b-1d0fef8554bf/"}]}}, {"id": "source:eff5922e101371e66c6fa7e287bc65b5cf721f7fc28b7dab3b5aa6a295c6bcc3", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "title": "Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries", "content_text": "For Immediate Release Chicago, IL \u2013 August 14, 2026 \u2013 Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-price", "date_published": "2026-08-14T09:38:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:00080bf9420de03300de7c149c296f3f345081ac0dcee7187c6ee511e8f63e22", "url": "https://finance.yahoo.com/markets/stocks/articles/centene-cnc-stock-still-looks-091638310.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/centene-cnc-stock-still-looks-091638310.html", "title": "Centene (CNC) Stock Still Looks Like A Bargain As Shares Jumped 145%", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how much of the recent optimism is already reflected in the price. Centene has returned 145.2% over the past year, which puts a spotlight on whether the recent share price strength is outpacing the underlying fundamentals. Raised expectations for future revenue and earnings, together with a plan to redeem part of its debt, can support the case for", "date_published": "2026-08-14T09:16:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CNC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CNC", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3a0023f4-b345-4574-97ec-c97fb67f4a94/"}]}}, {"id": "source:e142f91199ddc701efe333aa5e8027026f2517e3c090202450a3265d89e820a2", "url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "title": "Bekaert: Update on the Share Buyback Program and the Liquidity Agreement", "content_text": "Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to \u20ac 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 6 August 2026 to 12 August 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 56 000 shares. The table below provides an overview of the transactions under th", "date_published": "2026-08-14T06:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:628df1dfc51b43eaf5176f665aa8074ea9d077a0712fc5bd8d80d1a4d67c31c5", "url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "title": "AFARAK GROUP: INTERIM REPORT H1 2026", "content_text": "Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE (\"Afarak\" or \"the Company\") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR million 0.5 5.9 -2.6 Earnings before taxes EUR million 0.1 3.4 -7.5 (Loss) / Profit for the period EUR million -0.7 2.4 -8.9 Earnings per share EUR 0.00 0.01 -0.03 EBITDA margin 2.8% 9.0% -0.2 EBIT margin 0.8% 7.7% -1.8 Earnings margin 0.2% 4.5% -5.3 Personnel (end of period) 625 613 626 FIRST HALF 2026 HIGHLIGHTS The Group recorded an ", "date_published": "2026-08-14T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:350e8b0f908a191d1ec65427f675fa0c0434ffe64637da431ccf76d5a5533ef2", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "title": "Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Str", "date_published": "2026-08-14T03:16:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:73f203305b5d54485de2deb2823ca9b04af33338a782dd1b173d26623ce497c7", "url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "external_url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "title": "Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?", "content_text": "Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and other negatives, it makes sense why Wall Street isn't liking these merger rumors.10 stocks we like better than Bristol Myers Squibb \u203a In recent weeks, two pharmaceutical stocks, AstraZeneca(NYSE: AZN) and Bristol Myers Squibb(NYSE: BMY), have become the subject of merger rumors. At the start of the m", "date_published": "2026-08-14T02:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:65c852dc775c72b5502fcdeef2c90a9021dfa62ffb565c8da6ae1009c5ce2d46", "url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-technologies-gehc-stock-011218947.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-technologies-gehc-stock-011218947.html", "title": "GE HealthCare Technologies (GEHC) Stock Still Looks Cheap After A 20% Jump", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. GE HealthCare Technologies stock has climbed 19.7% over the past month, yet its valuation checks still lean toward the shares looking cheap rather than stretched. The 19.7% gain over the past month points to a sharp reset in expectations that puts the current pricing under closer scrutiny for new buyers and existing holders. Recent expansion of ultrasound and breast imaging platforms can support expectations for future revenue, while execution risks around", "date_published": "2026-08-14T01:12:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:6d94a2828794f443fb7600fc36fdf927e9d2536c40861e5a870a9d6ffbb4958c", "url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "title": "Could Danaher Corporation (DHR)\u2019s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?", "content_text": "When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower in response. That drop immediately spilled over to Bio-Rad Laboratories, Inc. (NYSE:BIO), holder of a $5 billion strategic stake in Sartorius, sending Bio-Rad shares down about 1% in early New York trading.", "date_published": "2026-08-14T00:13:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DHR"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DHR", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/fe21a17c-6fdf-42c3-8e76-19bd3a234024/"}]}}, {"id": "source:59981c612ce15cd1484b2e39a59c6766da4145fe74d1a0ccab2a5ad215535de6", "url": "https://finance.yahoo.com/healthcare/articles/incyte-corporation-incy-bigger-revenue-000444398.html", "external_url": "https://finance.yahoo.com/healthcare/articles/incyte-corporation-incy-bigger-revenue-000444398.html", "title": "Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?", "content_text": "On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. HALO secures an upfront payment, milestone payments, and royalties on commercial sales, with Incyte holding an option to nominate two additi", "date_published": "2026-08-14T00:04:44+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "INCY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "INCY", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/bfa37ebe-8823-4455-8296-972f2df07f8c/"}]}}, {"id": "source:fa653b52a5fbc565a19314567340cb7551b5057eca6e4c32041314cb69b78de4", "url": "https://finance.yahoo.com/healthcare/articles/could-arcus-biosciences-rcus-summit-000349349.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-arcus-biosciences-rcus-summit-000349349.html", "title": "Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)\u2019s Cancer Drug Partnership Create a New Treatment Standard?", "content_text": "On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2\u03b1 inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line metastatic disease. Arcus CEO Terry Rosen highlighted the opportunity to establish a well-tolerated, TKI-sparing regimen that could prolong survival and serve as a first-line backb", "date_published": "2026-08-14T00:03:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "SMMT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SMMT", "name": "Summit Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2c1758ce-a02e-47ef-b431-b60536a5b452/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ff588356-d255-49b7-b368-9d174cfc68c9/"}]}}, {"id": "source:e9910ce59642be6aa999514f06aedcc53452cf2fd331fe433b68b6c9c6898454", "url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "title": "MLP SE (WBO:MLP) (Q2 2026) Earnings Call Highlights: Record Revenue and EBIT Fuel Optimistic Outlook", "content_text": "This article first appeared on GuruFocus. Total Revenue: Increased by 10% to a record EUR583 million in the first half of 2026. EBIT: Reached a new record high of EUR64 million in the first half of 2026. Revenue by Competence Field: Property & Casualty grew 12%, Wealth grew 11%, and Life & Health was slightly above the previous year's levels. Assets Under Management: Increased to a new record level of EUR68.8 billion. Non-life Insurance Premium Volume: Reached a new record high of EUR865 million. Equity: Increased from EUR585 million to EUR589 million compared to the 2025 balance sheet date. R", "date_published": "2026-08-13T23:09:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYNN"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYNN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/03322f3a-4d3f-49c3-9d58-8d892e092fe9/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e19b7c19-526e-461d-afb3-c5bb3a18f4f2/"}]}}, {"id": "source:d24f03e171dcc6919f537e9491918e8c8f9a33221c26e24cf2891fd1bebba413", "url": "https://finance.yahoo.com/healthcare/articles/could-hca-healthcare-inc-hca-221733771.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-hca-healthcare-inc-hca-221733771.html", "title": "Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?", "content_text": "HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street. In its Q2 results, HCA Healthcare, Inc. reported that revenue increased 8.7% year-over-year to $20.23 billion from $18.61 billion in Q2 2025. The firm's net income attributable to the company rose 2.8% to $1.69 billion, while diluted EPS increased 11.6% to $7.62 (or $7.", "date_published": "2026-08-13T22:17:33+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HCA", "SMMT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HCA", "name": "HCA Healthcare, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bbe14341-13c5-40fe-8ae4-cb4c3fda399b/"}, {"symbol": "SMMT", "name": "Summit Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2c1758ce-a02e-47ef-b431-b60536a5b452/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1772476d-3e9d-4598-bb50-6351ded7a204/"}]}}, {"id": "source:928823bcde70bb7367b7a01d4b7cf5f0da09d639dff31e4c00c60b5634135b1b", "url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "title": "HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates", "content_text": "HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this medical technology company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. HeartFlow, which belongs to th", "date_published": "2026-08-13T21:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ff588356-d255-49b7-b368-9d174cfc68c9/"}]}}, {"id": "source:da2ac5f7d7e7a62f980a2a77120f080a8592a02900734cf5669e202a2453ffd8", "url": "https://finance.yahoo.com/healthcare/articles/hims-q2-deep-dive-ai-211700767.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-q2-deep-dive-ai-211700767.html", "title": "HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook", "content_text": "HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter's revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its non-GAAP loss of $0.09 per share was significantly below analysts' consensus estimates. Is now the time to buy HIMS? Find out in our full research report (it's free). Hims & Hers Health (HIMS) Q2 CY2026 Highlig", "date_published": "2026-08-13T21:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/122de5b2-fd50-439a-add0-9632363fa758/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2bdb2fd1-4905-4b9c-a83d-617c4c243696/"}]}}, {"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZTS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d99acf02-a6bb-4ac1-96cc-9b1cace7f412/"}]}}, {"id": "source:eb8d32537916312e97bafca18641db9eb940b0aea9bec1f79127025e04949542", "url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-ai-ultrasound-launches-191308464.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-ai-ultrasound-launches-191308464.html", "title": "How GE HealthCare\u2019s New AI Ultrasound Launches Could Shape GEHC\u2019s Diagnostic Edge for Investors", "content_text": "Earlier this month, GE HealthCare introduced the LOGIQ e Xi and LOGIQ e Si laptop ultrasound systems and launched the Invenia ABUS Prime and ABUS StreamVue breast imaging solutions, expanding its AI-enabled and cloud-connected ultrasound portfolio across multiple care settings. These product launches aim to standardize imaging workflows, support remote reading, and address dense-breast screening needs, potentially strengthening GE HealthCare's position in high-value, technologically advanced diagnostics. We'll now examine how this expansion in AI-powered, workflow-focused ultrasound solutions ", "date_published": "2026-08-13T19:13:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVOBN", "NVON"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}]}}, {"id": "source:3e581f92470f4b5afab1cad30e71ada24f26051a1dff74f9e42be0e418df6277", "url": "https://www.nasdaq.com/articles/ocugen-ocgn-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/ocugen-ocgn-q2-2026-earnings-call-transcript", "title": "Ocugen (OCGN) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman, Chief Executive Officer, and Co-Founder - Shankar MusunuriChief Financial Officer - Rita Johnson-GreeneExecutive Vice President of Commercial and Business Development - Abhi GuptaChief Medical Officer - Mohamed GeneadHead of Communications - Chris Clark Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Cash, Cash Equivalents, and Restricted Cash -- $100.4 million as of June 30, 2026, compared to $32.2 million as of March 31, 2026.Cash Runway -- Extended into 2028 following ", "date_published": "2026-08-13T18:14:44+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "OCGN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OCGN", "name": "Ocugen, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9feac636-96f2-4cb4-9ae2-979e66131a4b/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVOBN", "NVON"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}]}}, {"id": "source:9ffe2c00b2a37cdcea4a80a976a9d7e6f8e3a809762571c555c7e62d96d599f7", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "title": "Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of ", "date_published": "2026-08-13T17:11:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "GILD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1772476d-3e9d-4598-bb50-6351ded7a204/"}]}}, {"id": "source:0b0fb9490ab43a14a6f259c15ca65616328960edddf47dcbe17e6d04df9ccb3e", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-pediatrix-medical-smart-155300567.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heres-why-pediatrix-medical-smart-155300567.html", "title": "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio", "content_text": "Pediatrix Medical Group, Inc. MD is a physician services provider company that offers a range of services across various specialties, including obstetrics, maternal-fetal medicine and neonatology, complemented by multiple pediatric subspecialties. The company has gained 23.9% in the year-to-date period, outperforming the industry's 1.2% growth. MD \u2014 with a market cap of $2.2 billion \u2014is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are adding further support to revenue and earnings growt", "date_published": "2026-08-13T15:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:3bec54d3bf7ec8c391f4104861349aadc0e30456575983739eca1728f8680038", "url": "https://finance.yahoo.com/markets/stocks/articles/gehc-lmat-better-value-stock-154003397.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gehc-lmat-better-value-stock-154003397.html", "title": "GEHC or LMAT: Which Is the Better Value Stock Right Now?", "content_text": "Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specif", "date_published": "2026-08-13T15:40:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:ecd0d53289060f7914c53e120efc8e0a0a0a8e97dbd074319d2b81bfd733fdcc", "url": "https://finance.yahoo.com/healthcare/articles/carolina-complete-health-supports-young-154000860.html", "external_url": "https://finance.yahoo.com/healthcare/articles/carolina-complete-health-supports-young-154000860.html", "title": "Carolina Complete Health Supports Young Leaders Through AMEXCAN Summer Camp", "content_text": "Sponsorship helped 24 children from coastal North Carolina participate in educational, cultural and leadership-building activities CHARLOTTE, N.C., Aug. 13, 2026 /PRNewswire/ -- Carolina Complete Health, a subsidiary of the Centene Corporation (NYSE: CNC), sponsored the AMEXCAN Summer Camp, helping provide 24 children from coastal North Carolina with a summer experience centered on learning, leadership and personal growth.Carolina Complete Health Throughout the program, participants took part in educational workshops, cultural activities, leadership development and recreational programming des", "date_published": "2026-08-13T15:40:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "CNC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CNC", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3a0023f4-b345-4574-97ec-c97fb67f4a94/"}]}}, {"id": "source:33e32a55454fb0399fcd532ed23175ffd075d37280d0c841a24aff8a18065e15", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "title": "How Pfizer\u2019s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story", "content_text": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50\u2013US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer's autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology and dermatology pipeline. We'll now explore how Pfizer's higher 2026 revenue guidance, backed by non-COV", "date_published": "2026-08-13T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a25809d4-86bc-4675-a6db-84b1695cc584/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVOBN", "NVON"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVOBN", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/f8af74e2-0372-465c-b306-2b47187ca083/"}, {"symbol": "NVON", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fc6edd35-9731-4914-91d6-4963d8d82068/"}]}}, {"id": "source:8731f7effa586440d1d4919b715b969e8607c86f0ca67737b1e8547b3489afb6", "url": "https://seekingalpha.com/news/4632398-unitedhealth-faces-shareholder-suit-accusing-corporate-governance-failures?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632398-unitedhealth-faces-shareholder-suit-accusing-corporate-governance-failures?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "UnitedHealth faces shareholder suit accusing corporate governance failures", "content_text": "[UnitedHealthcare headquarters in Minnetonka, Minnesota, USA] JHVEPhoto/iStock Editorial via Getty Images UnitedHealth Group (UNH [https://seekingalpha.com/symbol/UNH]) is facing an amended shareholder lawsuit that accuses the insurer of knowing about serious governance issues and doing little to ensure compliance, leading to significant losses in stock value. The suit was filed in a Minnesota federal court by the Employees\u2019 Retirement System of the State of Rhode Island and L\u00e4nsf\u00f6rs\u00e4kringar Fondf\u00f6rvaltning AB, a Swedish asset manager. Plaintiffs blame the board and senior company officers. \"O", "date_published": "2026-08-13T14:18:07+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Capital return", "UNH"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/ce5961fd-8c14-4625-9f92-293ecbda77b5/"}]}}, {"id": "source:9d32db924ee34a6fd0c1a4bad9032b1acac67011e96847aee0aa81afd2b0fc08", "url": "https://finance.yahoo.com/healthcare/articles/humana-improve-caregiver-retention-healthstream-141700367.html", "external_url": "https://finance.yahoo.com/healthcare/articles/humana-improve-caregiver-retention-healthstream-141700367.html", "title": "Can Humana Improve Caregiver Retention With HealthStream Deal?", "content_text": "Humana Inc.'s HUM Medicaid managed care plan, Humana Healthy Horizons, is teaming up with HealthStream in Indiana to strengthen the state's home-care workforce. Under the initiative, Humana is sponsoring 1,000 Home Health Aide scholarships, helping remove financial barriers for people entering the caregiving field. The program uses HealthStream's Career Network to reach rural and underserved communities, where worker shortages can restrict access to home-based care. Humana is also deploying HealthStream's CoachUp Care platform, predictive analytics and training tools to help providers recruit ", "date_published": "2026-08-13T14:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "HUM"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HUM", "name": "Humana Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/225de6b3-cae3-4bd3-b3ab-282953f91c97/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "external_url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026. Per management, the SuperFlex system represents a significan", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}, {"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BIIB"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIIB", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/afe83992-07f6-4f9e-a80a-6faafb26e903/"}]}}, {"id": "source:94864b78b6281fa043ef47f6a4ab238ba5776c49580b8f36e8fbbb63ea9c121d", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-backs-long-133733648.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-backs-long-133733648.html", "title": "Intuitive Surgical (ISRG) Backs Long-Term Moat Amid Near-Term Volatility", "content_text": "TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, driven by resilient economic growth and strong corporate earnings. April marked a recovery from March lows, with the S&P 500 achieving record highs by early June, largely due to robust corporate earnings linked to AI capital spendi", "date_published": "2026-08-13T13:37:33+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:c9f8b0bb43fdc75af27a72e2a94fb69b2b914b52e2eba9e72edcb333236b4303", "url": "https://finance.yahoo.com/healthcare/articles/mhs-serves-announces-recipients-over-133000474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/mhs-serves-announces-recipients-over-133000474.html", "title": "MHS Serves Announces Recipients of over $2 Million Investment in Hoosier Employment", "content_text": "INDIANAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Managed Health Services (MHS), a managed care entity that has been proudly serving the state of Indiana for 30 years and a Centene (NYSE: CNC) company, is proud to announce the recipients of the MHS Serves Workforce Support Program, a new statewide funding opportunity in partnership with Indiana Minority Health Coalition (IMHC) and Black Onyx Management, designed to strengthen workforce development programs that help Medicaid members prepare for employment, increase their income and build long-term economic stability.MHS The program will provide fund", "date_published": "2026-08-13T13:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "CNC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CNC", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3a0023f4-b345-4574-97ec-c97fb67f4a94/"}]}}, {"id": "source:627655aaef2ff927e3ded200aca76be0526bafd2af9b4cfcf1b6643417140ea2", "url": "https://finance.yahoo.com/healthcare/articles/insulet-corporation-podd-wearable-pod-130437669.html", "external_url": "https://finance.yahoo.com/healthcare/articles/insulet-corporation-podd-wearable-pod-130437669.html", "title": "Insulet Corporation\u2019s (PODD) Wearable Pod Tech Finds New Frontier", "content_text": "Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the \"Insiders Fund\". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500's -0.95%, 15.2%, and 9.98% returns, respectively, over the same period. The fund underperformed while the S&P 500 and Nasdaq-100 posted their best quarter in six years. A significant factor in this decline is a ~30% concentration in Alphabet stock, which shifted from a cash-generating asset to a capital-intensive postur", "date_published": "2026-08-13T13:04:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PODD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/ddc4e846-4b3d-49f0-9696-0f35675b981e/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:e62631285d7721245ec3e28a17d057d0d95d03a031f7951167d433420fe5c569", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "title": "Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle", "content_text": "Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter \"wasn't a huge catch up thus year not yet de-risked,\" leaving \"a higher-than-normal burden on 2H to deliver.\" As a result, Wolfe sees the near-term skew to estimates \"leans negative,\" with growth \"more likely to slow to 8% vs speed up to 10% in 2027.\" The firm flagged that Stryker'", "date_published": "2026-08-13T12:37:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:36f6ed0610f17ab8c61df9722e382060654627cc26f4a2cbaacc208156886924", "url": "https://finance.yahoo.com/healthcare/articles/bd-bdx-q3-2026-earnings-122827670.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bd-bdx-q3-2026-earnings-122827670.html", "title": "BD (BDX) Q3 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Shawn Bevec Chairman, Chief Executive Officer and President - Tom Polen Executive Vice President and Chief Financial Officer - Vitor Roque Full Conference Call Transcript Operator: Hello, and welcome to BD's Third Fiscal Quarter 2026 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 688-9445 for domestic calls and area code +1 402-220-1", "date_published": "2026-08-13T12:28:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BDX", "name": "Becton, Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/ea5c3141-6554-4729-876f-fabf636b12e0/"}]}}]}